BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 10081512)

  • 21. Human immunodeficiency virus type 1-infected persons with residual disease and virus reservoirs on suppressive highly active antiretroviral therapy can be stratified into relevant virologic and immunologic subgroups.
    Dornadula G; Nunnari G; Vanella M; Roman J; Babinchak T; DeSimone J; Stern J; Braffman M; Zhang H; Pomerantz RJ
    J Infect Dis; 2001 Jun; 183(11):1682-7. PubMed ID: 11343220
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
    Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
    AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of two distinct subsets of long-term nonprogressors with divergent viral activity by stromal-derived factor 1 chemokine gene polymorphism analysis.
    Balotta C; Bagnarelli P; Corvasce S; Mazzucchelli R; Colombo MC; Papagno L; Santambrogio S; Ridolfo AL; Violin M; Berlusconi A; Velleca R; Facchi G; Moroni M; Clementi M; Galli M
    J Infect Dis; 1999 Aug; 180(2):285-9. PubMed ID: 10395841
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Linking Nef with the immunological and virological determinants of AIDS].
    Gómez-Icazbalceta G; Larralde C
    Rev Invest Clin; 2009; 61(3):243-51. PubMed ID: 19736813
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Decrease in hospitalization and mortality rates among children with perinatally acquired HIV type 1 infection receiving highly active antiretroviral therapy.
    Viani RM; Araneta MR; Deville JG; Spector SA
    Clin Infect Dis; 2004 Sep; 39(5):725-31. PubMed ID: 15356789
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Factors affecting the natural history of human immunodeficiency virus infection.
    Pinching AJ
    Immunodefic Rev; 1988; 1(1):23-38. PubMed ID: 2908507
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Virological and immunological impact of tuberculosis on human immunodeficiency virus type 1 disease.
    Toossi Z
    J Infect Dis; 2003 Oct; 188(8):1146-55. PubMed ID: 14551885
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The impact of HIV tropism on decreases in CD4 cell count, clinical progression, and subsequent response to a first antiretroviral therapy regimen.
    Waters L; Mandalia S; Randell P; Wildfire A; Gazzard B; Moyle G
    Clin Infect Dis; 2008 May; 46(10):1617-23. PubMed ID: 18419499
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HIV infections and AIDS development: the role of adjuvant activation.
    Grassi HC; Andrade ED
    Med Hypotheses; 2001 Dec; 57(6):693-6. PubMed ID: 11918427
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Natural history and pathogenesis of human immunodeficiency virus infection.
    Burger S; Poles MA
    Semin Liver Dis; 2003 May; 23(2):115-24. PubMed ID: 12800065
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term nonprogressive infection with human immunodeficiency virus type 1 in a hemophilia cohort.
    Greenough TC; Brettler DB; Kirchhoff F; Alexander L; Desrosiers RC; O'Brien SJ; Somasundaran M; Luzuriaga K; Sullivan JL
    J Infect Dis; 1999 Dec; 180(6):1790-802. PubMed ID: 10558933
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The pathogenesis of HIV infection.
    Ortona L; Antinori A
    Rays; 1994; 19(1):15-28. PubMed ID: 7913242
    [No Abstract]   [Full Text] [Related]  

  • 33. Notes on the pathogenesis of human immunodeficiency virus infection.
    Piconi S; Clerici M
    Ann Ist Super Sanita; 1997; 33(2):219-23. PubMed ID: 9470244
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Directions in HIV/AIDS research. A Minnesota perspective.
    Henry K; Melroe H; Nelson R
    Minn Med; 1995 Nov; 78(11):26-34. PubMed ID: 8531902
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Replication rate and evolution in the human immunodeficiency virus.
    Kelly JK
    J Theor Biol; 1996 Jun; 180(4):359-64. PubMed ID: 8776467
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Viral activity in early HIV disease.
    Freedman AR; Scadden DT
    Curr Opin Hematol; 1994 Jan; 1(1):19-23. PubMed ID: 9371255
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Features of human immunodeficiency virus infection and disease.
    Levy JA
    Pediatr Res; 1993 Jan; 33(1 Suppl):S63-9; discussion S69-70. PubMed ID: 8433877
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [From HIV infection to AIDS].
    Gluckman JC; Klatzmann D
    Nouv Rev Fr Hematol (1978); 1987; 29(1):9-12. PubMed ID: 3647357
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Testing for HIV infection in time: scientific reasons.
    Koblet H
    Schweiz Med Wochenschr; 1998 Apr; 128(15):586-97. PubMed ID: 9606800
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The pathogenesis of HIV-1 infection.
    Weber J
    Br Med Bull; 2001; 58():61-72. PubMed ID: 11714624
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.